gojaro is a medicine containing tirzepatide — a dual GIP and GLP-1 receptor agonist administered once weekly by subcutaneous injection.
Tirzepatide binds and activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.
Injected under the skin — thigh, abdomen (at least 5 cm from the belly button), or back of the upper arm — once per week.
Each vial contains one dose only. The cap colour indicates the dose strength. Do not reuse a vial, syringe, or needle.
gojaro solution should be clear and colourless to slightly yellow. Do not use if the medicine has been frozen, has particles, is cloudy, or is discoloured.
Confirm the medicine name and dose strength on the vial label matches your recommended strength before every injection.
This site provides information about gojaro (tirzepatide) for healthcare professionals and patients who have been prescribed the medicine. It is not medical advice. Always follow the guidance of your prescriber. If you experience a serious side effect, contact your healthcare provider immediately.